Biocartis Group NV
XBRU:BCART
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.29
0.29
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biocartis Group NV
Biocartis Group NV
Note Receivable
Biocartis Group NV
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biocartis Group NV
XBRU:BCART
|
Note Receivable
€204k
|
CAGR 3-Years
150%
|
CAGR 5-Years
79%
|
CAGR 10-Years
N/A
|
|
|
Nyxoah SA
XBRU:NYXH
|
Note Receivable
€1.2m
|
CAGR 3-Years
134%
|
CAGR 5-Years
77%
|
CAGR 10-Years
N/A
|
|
|
Ion Beam Applications SA
XBRU:IBAB
|
Note Receivable
€13.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Sequana Medical NV
XBRU:SEQUA
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biocartis Group NV
Glance View
Biocartis Group NV which engages in the development of oncology molecular diagnostic solutions. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 619 full-time employees. The company went IPO on 2015-04-27. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
See Also
What is Biocartis Group NV's Note Receivable?
Note Receivable
204k
EUR
Based on the financial report for Jun 30, 2023, Biocartis Group NV's Note Receivable amounts to 204k EUR.
What is Biocartis Group NV's Note Receivable growth rate?
Note Receivable CAGR 5Y
79%
The average annual Note Receivable growth rates for Biocartis Group NV have been 150% over the past three years , 79% over the past five years .
You don't have any saved screeners yet
